uniQure N.V. (LON:0EE0)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 1.10B +67.2% |
| Revenue (ttm) | 11.72M -44.9% |
| Net Income | -174.93M |
| EPS | -3.23 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,965 |
| Average Volume | 11,700 |
| Open | 24.32 |
| Previous Close | 23.98 |
| Day's Range | 22.90 - 24.73 |
| 52-Week Range | 7.91 - 71.16 |
| Beta | 0.68 |
| RSI | 47.91 |
| Earnings Date | Feb 27, 2026 |
About uniQure
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase ... [Read more]
Financial Performance
In 2024, uniQure's revenue was $27.12 million, an increase of 71.17% compared to the previous year's $15.84 million. Losses were -$239.56 million, -22.34% less than in 2023.
Financial numbers in USD Financial StatementsNews
Early uniQure Fabry Trial Shows Lasting Enzyme Boost, Safety Watch
uniQure shares early trial data showing strong enzyme increases in Fabry patients, manageable safety results, and paused higher dosing after liver enzyme findings. ... Full story available on Benzinga...
Early uniQure Fabry Trial Shows Lasting Enzyme Boost, Safety Watch
uniQure N.V. (NASDAQ: QURE) on Friday announced updated preliminary safety and exploratory efficacy data from 11 patients in its Phase 1/2a trial of AMT-191.
uniQure (QURE) Shares Promising Data on Gene Therapy for Fabry Disease
uniQure (QURE) Shares Promising Data on Gene Therapy for Fabry Disease
uniQure Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease
~ Supraphysiological expression of α-Gal A activity maintained for over a year in longest treated patient as of data cutoff date ~
QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm
RADNOR, Pa., Feb. 1, 2026 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of ...
QURE Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm
RADNOR, Pa., Jan. 30, 2026 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behal...
Alger Small Cap Focus Fund Q4 2025 Portfolio Update
Class A shares of the Alger Small Cap Focus Fund outperformed the Russell 2000 Growth Index during the fourth quarter of 2025. Exact Sciences Corporation, Guardant Health, Inc., and Natera, Inc. were ...
QURE Makes Notable Cross Below Critical Moving Average
In trading on Wednesday, shares of uniQure N.V. (Symbol: QURE) crossed below their 200 day moving average of $23.97, changing hands as low as $23.63 per share. uniQure N.V. shares are currently tradin...
Barclays Initiates Coverage on uniQure (QURE) with Equal-Weight Rating | QURE Stock News
Barclays Initiates Coverage on uniQure (QURE) with Equal-Weight Rating | QURE Stock News
UNIQURE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating uniQure N.V.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In uniQure (QURE) To Contact Him Directly To Discuss Their Options
Tema Heart & Health ETF Buys 6,455 Shares of uniQure NV (QURE)
Tema Heart & Health ETF Buys 6,455 Shares of uniQure NV (QURE)
TOTH FINANCIAL ADVISORY CORP Sells 65 Shares of uniQure NV (QURE)
TOTH FINANCIAL ADVISORY CORP Sells 65 Shares of uniQure NV (QURE)
Notice of QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm
RADNOR, Pa., Jan. 17, 2026 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of...
QURE Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm
RADNOR, Pa., Jan. 16, 2026 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behal...
QURE Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm
RADNOR, Pa., Jan. 12, 2026 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behal...
uniQure Stock Jumps After Scheduling FDA Type A Meeting For AMT‑130 Approval Pathway
uniQure N.V. (NASDAQ:QURE) shares are popping on Friday after the company ... Full story available on Benzinga.com
uniQure (QURE) Surges on FDA Meeting for Gene Therapy Approval
uniQure (QURE) Surges on FDA Meeting for Gene Therapy Approval
UniQure Announces FDA Type A Meeting To Discuss BLA Data For Huntington's Gene Therapy
(RTTNews) - uniQure N.V. (QURE) today announced that a Type A meeting with the FDA has been scheduled to discuss the Biologics License Application (BLA) data package intended to support accelerated ap...
uniQure gains as FDA sets up meeting on gene therapy
uniQure (QURE) stock jumps after FDA schedules a Type A meeting to discuss a potential accelerated approval for its AMT-130 gene therapy. Read more here.
uniQure's (QURE) Gene Therapy for Huntington's Disease Advances with FDA Meeting
uniQure's (QURE) Gene Therapy for Huntington's Disease Advances with FDA Meeting
uniQure Announces Type A Meeting Scheduled with FDA
LEXINGTON, Mass. and AMSTERDAM, Jan. 09, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs,...
QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm
RADNOR, Pa., Jan. 8, 2026 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of ...
uniQure: Now What?
uniQure faces a major setback as the FDA reversed its stance on using external controls for AMT-130's approval, delaying its BLA submission. QURE's pivotal Phase 1/2 trial showed 75% slowing in cUHDRS...
QURE Investigation: Investors Encouraged to Contact Kirby McInerney LLP
NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors its investigation on behalf of uniQure N.V. (“uniQure” or the “Company”) (NASDAQ:QURE) investors concerning the Company...
uniQure Breaks Below 200-Day Moving Average - Notable for QURE
In trading on Monday, shares of uniQure N.V. (Symbol: QURE) crossed below their 200 day moving average of $23.05, changing hands as low as $22.15 per share. uniQure N.V. shares are currently trading o...